Revenue
2020
2021
2022
2023
2024
2025
Ose Immunotherapeutics (OSE)
Price€2.99Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | €2.6M | €69.9M | €2.2M | €18.3M | €26.3M | €10.4M |
| Research & development | €33.9M | €30.4M | €17.2M | €26.9M | €30.6M | €22.4M |
| Operating expenses | €39.2M | €26.3M | €25.3M | €36.7M | — | — |
| Operating income | −€37.5M | €43.7M | −€23.0M | −€18.5M | −€16.6M | −€19.0M |
| Operating margin | −1,431.31% | 62.59% | −1,032.15% | −100.95% | −63.20% | −182.03% |
| EBITDA | −€31.3M | €46.3M | −€20.3M | −€15.7M | −€14.7M | −€18.7M |
| EBITDA margin | −1,196.83% | 66.28% | −911.85% | −85.68% | −55.71% | −179.41% |
| Net income | −€37.7M | €37.4M | −€23.0M | −€17.8M | −€16.9M | −€16.6M |
| Net profit margin | −1,439.06% | 53.59% | −1,032.91% | −97.04% | −64.05% | −158.69% |
| Basic EPSper basic share | -€1.69 | €1.71 | -€1.18 | -€0.96 | -€0.93 | -€1.06 |
| Diluted EPSper diluted share | -€1.69 | €1.46 | -€1.18 | -€0.96 | -€0.93 | -€1.06 |